Vitreous form of known bradykinin antagonist
US7094899B2 · kind B2 · utility
0Cited by
1References
3Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 22, 2002 |
| Grant date | Aug 22, 2006 |
| Priority date | — |
| Expiry date | Nov 22, 2022 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P37/08
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention relates to a vitreous form of 8-[3-[N-[(E)-3-(6-acetamidopyridin-3-yl)acryloylglycyl]-N-methylamino]-2,6-dichlorobenzyloxy]-2-methylquinoline (FR173657). This vitreous form has good solid stability and, therefor, is useful for producing and supplying FR173657 products whose quality is stable enough to be suitable for medicines.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.